Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 16/20 | 0.51 |
| ▸ | ESR1 | P03372 | 8/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ESRRB | O95718 | 2/20 | 0.39 |
| ▸ | ESRRG | P62508 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1531798 | 1.00 | ESR2 (0.51) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL1509710 | 0.87 | HRH3 (0.45) | CYP3A4CYP2C9KCNH2 | |
| SCHEMBL1509709 | 0.87 | HRH3 (0.45) | CYP3A4CYP2C9KCNH2 | |
| SCHEMBL4285603 | 0.85 | ESR2 (0.34) | ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL4285599 | 0.85 | ESR2 (0.34) | ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL12001925 | 0.80 | ESR2 (0.53) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL10684492 | 0.78 | GAA (0.35) | — | |
| SCHEMBL13096848 | 0.78 | GAA (0.35) | — | |
| SCHEMBL10687104 | 0.78 | GAA (0.35) | — | |
| SCHEMBL3098673 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2698411-B9 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2698411-B1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2698413-B1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2016-12-28 | — | — | EP | disclosed |
| EP-2303987-B9 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-2303987-B1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2698413-A2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2698411-A2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2303988-B9 | LIQUID CRYSTAL COMPOSITIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2013-12-25 | — | — | EP | disclosed |
| CN-102076820-B | Liquid crystal compositions comprising compounds containing mesogen | TRANSITIONS OPTICAL INC | 2013-11-27 | — | — | CN | disclosed |
| EP-2303988-B1 | LIQUID CRYSTAL COMPOSITIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2303987-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2303988-A1 | LIQUID CRYSTAL COMPOSITIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7910019-B2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910020-B2 | Liquid crystal compositions comprising mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100014010-A1 | FORMULATIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090326186-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090323012-A1 | LIQUID CRYSTAL COMPOSITIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPITCAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009158483-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158488-A1 | LIQUID CRYSTAL COMPOSITIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100014010-A1 | FORMULATIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | MYOC, RARG, MTX2 | ESR2 2029/4885ESR1 3752/4885CYP3A4 1538/4885 |
| US-20090326186-A1 | MESOGEN CONTAINING COMPOUNDS | MYOC, BMP2, RARG | ESR2 1645/4885ESR1 3562/4885CYP3A4 2065/4885 |
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | MYOC, BMP2, RARG | ESR2 1645/4885ESR1 3562/4885CYP3A4 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.